Online first
Current issue
Archive
Special Issues
About the Journal
Publication Ethics
Anti-Plagiarism system
Instructions for Authors
Instructions for Reviewers
Editorial Board
Editorial Office
Contact
Reviewers
All Reviewers
2023
2022
2021
2020
2019
2018
2017
2016
General Data Protection Regulation (RODO)
REVIEW PAPER
Mental illness and metabolic syndrome – a literature review
1
Department of Applied Psychology, University, Lublin, Poland
2
Chair and Department of Human Physiology, Medical University, Lublin, Poland
Corresponding author
Ann Agric Environ Med. 2014;21(4):815-821
KEYWORDS
ABSTRACT
introduction and objective:
Researchers’ opinions are divided on whether metabolic syndrome is a separate clinical entity. Undoubtedly, the components of the syndrome, such as abdominal obesity, hypertension, impaired glucose tolerance, hypertriglyceridaemia, adversely affect metabolism, bringing with it a number of consequences, including type 2 diabetes and cardiovascular disease which significantly impair the quality of life.
Abbreviated description of the state of knowledge:
In recent years, much attention has been paid to research on the prevalence of metabolic disorders in mentally ill patients. This is due to a growing awareness that some antipsychotic medications contribute to weight gain in patients suffering from mental illness, and consequently lead to the development of a number of interrelated somatic factors, such as abdominal obesity, impaired glucose tolerance, hypertriglyceridaemia, and hypertension. Weight gain and other metabolic syndrome components have been noticed not only in patients, but also in their families. This paper presents current research on the prevalence of metabolic syndrome in people with mental illness. An analysis of the causes of metabolic disorders in this population has been conducted, including the role of the hypothalamic-pituitary-adrenal axis and cortisol secretion in the development of components of metabolic syndrome.
Conclusions:
Components of the metabolic syndrome are especially observed in mentally ill people. The mechanisms of their formation are not fully understood. A large role in their formation besides the negative effects of antipsychotic medication and specific lifestyle, play a specific dysregulation of the hypothalamic-pituitary-adrenal axis. Undoubtedly, further research and analysis in this area is necessary.
Researchers’ opinions are divided on whether metabolic syndrome is a separate clinical entity. Undoubtedly, the components of the syndrome, such as abdominal obesity, hypertension, impaired glucose tolerance, hypertriglyceridaemia, adversely affect metabolism, bringing with it a number of consequences, including type 2 diabetes and cardiovascular disease which significantly impair the quality of life.
Abbreviated description of the state of knowledge:
In recent years, much attention has been paid to research on the prevalence of metabolic disorders in mentally ill patients. This is due to a growing awareness that some antipsychotic medications contribute to weight gain in patients suffering from mental illness, and consequently lead to the development of a number of interrelated somatic factors, such as abdominal obesity, impaired glucose tolerance, hypertriglyceridaemia, and hypertension. Weight gain and other metabolic syndrome components have been noticed not only in patients, but also in their families. This paper presents current research on the prevalence of metabolic syndrome in people with mental illness. An analysis of the causes of metabolic disorders in this population has been conducted, including the role of the hypothalamic-pituitary-adrenal axis and cortisol secretion in the development of components of metabolic syndrome.
Conclusions:
Components of the metabolic syndrome are especially observed in mentally ill people. The mechanisms of their formation are not fully understood. A large role in their formation besides the negative effects of antipsychotic medication and specific lifestyle, play a specific dysregulation of the hypothalamic-pituitary-adrenal axis. Undoubtedly, further research and analysis in this area is necessary.
REFERENCES (53)
1.
Hansson L. Determinants of quality of life In people with severe mental illness. Acta Psychiatr Scand Suppl. 2006; (429): 46–50.
2.
Talarowska M, Florkowski A, Orzechowska A, Zbolarski K, Wysokiński A. Konsekwencje psychologiczne zespołu metabolicznego. Psychiatria w Praktyce Klinicznej, tom1. Via Medica, 2008.p.67–73 (in Polish).
3.
De Hert M, Correll ChU, Bobes J, Cetkovich-Bakmas M, Cohen D, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. Wolrd Psychiatry 2011; 52–77.
4.
Joukamaa M, Heliovaara M, Knekt P, Raitasalo AAR. Mental disorders and cause — specific mortality. Br J Psychiatry. 2001; 179: 498–502.
5.
Narasimhan M, Raynor JD. Evidence-Based Perspective on Metabolic Syndrome and Use of Antipsychotics. Drug Benefit Trends. 2010; 22: 77–88.
6.
Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009; 60: 147–156.
7.
Rabe-Jabłońska J. Występowanie, chorobowość i śmiertelność z powodu zespołu metabolicznego u chorych na schizofrenię. Ograniczenia terapeutyczne i wybór właściwego leku przeciwpsychotycznego. Psychiatria 2006; 3(4): 148–153 (in Polish).
8.
Newcomber JW. Metabolic syndrome and Mental Illness. Am J Manag Care. 2007;13 (7 Suppl): 170–177.
9.
Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005; 80(1): 9–18.
10.
Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition, NHLBI/AHA. Conference Proceedings http://circ.ahajournals.org/co... (access: 2013.04.07).
11.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
12.
Pacholczyk M, Ferenc T, Kowalski J, Zespół metaboliczny. Część I: Definicje i kryteria rozpoznawania zespołu metabolicznego. Epidemiologia oraz związek z ryzykiem chorób sercowo-naczyniowych i cukrzycy typu 2. Postepy Hig Med Dosw. 2008; 62: 530–542 (in Polish).
13.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7): 539–553.
14.
Zawiasa A, Nowicki M. Zespół metaboliczny u pacjentów po transplantacji narządów unaczynionych. Postępy Nauk Medycznych 2010; 3: 227–232 (in Polish).
15.
Pawłowska J, Witkowski JM, Bryl E. Zespół metaboliczny-rys historyczny i współczesność; Wybrane Problemy Kliniczne. Via Medica, 2009.p.222–228 (in Polish).
16.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16(5): 442–443.
17.
Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005; 51(6): 931–938.
18.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486–2497.
19.
Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation. 2007; 116(19): 2119–2126.
20.
Alberti G, Zimmet PZ, Shaw J. Grundy SM, International Diabetes Federation 2006: The IDF consensus worldwide definition of the metabolic syndrome http://www.idf.org/webdata/doc.... (access: 2013.04.07).
21.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223.
22.
Drzycińska-Tatka B, Drab-Rybczyńska A, Kasprzaj J. Zespół metaboliczny – epidemia XXI wieku 2011. Hygeia Public Healt. 2011; 46(4): 423–430 (in Polish).
23.
Dudek D. Zespół metaboliczny u pacjentów ze schizofrenią. Via Medica 2010.p.123–130 (in Polish).
24.
Foguet Boreu Q, Roura Poch P, Bullón Chia A, Mauri Martin C, Gordo Serra N, Cecília Costa R. en representación del grupo de Riesgo Cardiovascular en Trastorno Mental Severo (RISCA-TMS, Cardiovascular risk factors, cardiovascular risk and quality of life in patients with a severe mental disorder). Aten Primaria. 2013; 45(3): 141–148. doi: 10.1016/j.aprim.2012.10.010.
25.
Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005; 28(11): 2745–2749.
26.
Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, et al. The European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab. 2002; 28: 364–376.
27.
Toalson P, Saeeduddin A, Hardy T, Kabinoff G. The metabolic syndrome in patients with severe mental illness. Journal of Clinical Psychiatry 2004; 6(4): 152- 158.
28.
Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hinntikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003; 64: 575–579.
29.
Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, et al. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Research 2012; 200(2–3): 1035–1037.
30.
Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. CLAMORS Study Collaborative Group Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007; 90(1–3): 162–173.
31.
Ryan MC, Collins P, Thakore JH, Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160(2): 284–289.
32.
Duda-Sobczak A, Wierusz-Wysocka B. Cukrzyca a choroby psychiczne. Psychiatria Polska 2011, XLV(4): 589–598 (in Polish).
33.
Fabio P, Polsinelli G, Borlido C, Monda M, Vincenzo De Luca. The Role of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-Genetic Factors. Journal of Obesity 2012; 7. doi:10.1155/2012/572848.
34.
Meder J, Tyszkowska M, Jarema M, Araszkiewicz A, Szafrański T. Leki przeciwpsychotyczne w praktyce lekarza psychiatry. Leczenie pacjentów z rozpoznaniem schizofrenii lekoopornej. Psychiatria Polska 2008; XLII(6): 859–873 (in Polish).
35.
Rzewuska M. Zaburzenia metaboliczne związane ze stosowaniem LPP u chorych na schizofrenię. Psychiatria Polska 2007; XLI(4): 457–472 (in Polish).
36.
Lindenmayer JP, Czobora P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in Patients with schiophrenia treated with typical or atypical antipsychotics.Am. British Journal of Psychiatry 2003; 160: 290–296.
37.
Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002; 59: 1021–1026.
38.
Brunero S, Lamont S, Fairbrother G. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs. 2009; 23(3): 261–268.
39.
Palinkas LA, Lee PP, Barrett-Connor E. A prospective study of Type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med. 2004; 21(11): 1185–1191.
40.
Palinkas LA, Wingard DL, Barrett-Connor E. Depressive symptoms in overweight and obese older adults: a test of the “jolly fat” hypothesis. J Psychosom Res. 1996; 40(1): 59–66.
41.
Roberts RE, Deleger S, Strawbridge WJ, Kaplan G. Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes Relat Metab Disord. 2003; 27(4): 514–521.
42.
Gil K, Radziwiłłowicz P, Zdrojewski T, Piwoński J, Landowski J, Wyrzykowski B. Relationship between the prevalence of depressive symptoms and metabolic syndrom. Results of the SOPKARD Project. Kardiol Pol. 2006; 64: 464–459.
43.
Glueck C, Tieger M, Kunkel R, Tracy T, Speirs J, et al. Improvement in symptoms of depression and in an index of life stressors accompany treatment of severe hypertriglyceridemia. Biol Psychiatry 1993; 34: 240–252.
44.
Wysokiński A, Kłoszewska I. Zespół metaboliczny i zaburzenia depresyjne – przegląd piśmiennictwa. Psychiatria 2011; 8(2): 46–52.
45.
Beszczyńska B. Molekularne podstawy zaburzeń psychicznych wywołanych stresem, Postępy Hig Med Dosw. 2007; 690–701 (in Polish).
46.
Raikkonen K, Matthews K, Kuller L. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metabolism 2002; 51: 1573–1577.
47.
Weber-Hamann B, Hentschel F, Kniest A. Deuschle M, Colla M, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med. 2002; 64: 274–327.
48.
Hartley TA, Knox SS, Fekedulegn D, Barbosa-Leiker C, Violanti JM, et al. Association between Depressive Symptoms and Metabolic Syndrome in Police Officers: Results from Two Cross-Sectional Studies. Journal of Environmental and Public Health 2012; 9.
49.
Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, et al. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosomatic Medicine 2002; 64(3): 418–435.
50.
Ganong W F, Lewin-Kowalik J (eds.). Fizjologia. PZWL, 2007.p.230–238 (in Polish).
51.
Corcoran C, Walker E, Huot R, Mittal V, Messner K, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003; 29: 671–692.
52.
Walker E, Huot R, Mittal V, Messner K, Kestler L, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003; 29: 671–692.
53.
Goodyer IM, Park, RJ, Herbert J. Psychosocial and endocrine features of chronic first-episode major depression in 8–16 year olds. Biological Psychiatry 2001; 5O(5): 351–357.
Share
RELATED ARTICLE
| eISSN: | 1898-2263 |
| ISSN: | 1232-1966 |
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
© 2006-2024 Journal hosting platform by Bentus
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
